Richard Lowenthal

Richard Lowenthal is the President, Chief Executive Officer and co-founder of ARS Pharmaceuticals, Inc. With over 28 years of biotechnology and pharmaceutical development experience in various roles at both small and large companies, Mr. Lowenthal is a seasoned executive with expertise in strategic drug and global development, executive leadership, regulatory affairs, quality assurance and product registration of new drugs and biologics in the United States, Europe and Japan.

Dedicated to the support of pharmaceutical, biotechnology and investment companies, in 2007 Mr. Lowenthal founded Pacific-Link Regulatory Consulting and Research (PLC), where he provided leadership and mentoring on clinical development, regulatory affairs, quality assurance, licensing and investment opportunities. PLC supported the clinical and regulatory development of Valtoco (diazepam nasal spray) for acute repetitive seizures in support of Neurelis and managed the approval in early 2020. Valtoco is the first emergency rescue product that uses both the IntravailÒ technology and the Aptar UDS in epilepsy patients age six and greater.

Prior to ARS Pharmaceuticals, Inc., and PLC, Inc., Mr. Lowenthal held many leadership roles that included Vice President of Regulatory Affairs and quality assurance for Cadence Pharmaceuticals; Head of Worldwide Regulatory Affairs, Quality Assurance and Drug Safety for Maxim Pharmaceuticals, Inc.; Vice President of Regulatory Affairs and Quality Assurance for AnGes, MG, Inc.; Global Project Leader and Global Director of Regulatory Affairs for Janssen Research Foundation; Director of Regulatory Affairs and Quality Assurance for Somerset Pharmaceuticals Inc.; and New Drug Review Chemist for the U.S. Food and Drug Administration in the Division of Neuropharmacologic Drug Products and the Division of Oncology and Pulmonary Drug Products.

Mr. Lowenthal holds an M.Sc. in organic chemistry from Florida State University and a Master’s in Business for Executive Leadership from the University of San Diego. He has served as past chair of the American Association of Pharmaceutical Scientists (San Diego region), as well as member of the USP Biotechnology Expert Committee, chair of the Virology Working group, member of the National Organization of Rare Disease Corporate Council and has worked with various PhRMA and ICH Working Groups.